Translate this page into:
Erratum
doi: 10.4103/0378-6323.292501
PMID: 32820738
Erratum: Future therapies in melasma: What lies ahead?
Correspondence Address:
Published: 19-Aug-2020
How to cite this article: . Erratum: Future therapies in melasma: What lies ahead?. Indian J Dermatol Venereol Leprol 2020;86:608 |
Copyright: (C)2020 Indian Journal of Dermatology, Venereology, and Leprology
In the article titled “Future therapies in melasma: What lies ahead?”, published in pages 8-17, issue 1, vol. 86 of Indian Journal of Dermatology, Venereology and Leprology[1], there are figure citations and legend mismatches:
- Fig 2: Legend -Drugs targeting hyperactive melanocytes, to be cited after 'Newer agents targeting hyperactive melanocytes' (Pg.9); (Current Fig. 2 citation- to be removed)
- Fig 4- Legend 'Drugs targeting melanosome transfer to keratinocytes. To be cited after the subheading: 'Newer agents targeting melanosomal transfer' (Pg.11)
- [Figure 5]: Legend 'Role of a defective skin barrier in melasma'; [Figure 4] cited currently on page 11 to be cited as [figure 5]. (Current Fig 5 citation – to be removed)
- [Figure 6]: Legend 'Role of Endocrine factors in melasma'. [Figure 6] to be cited on page 12 after 'Newer agents targeting hormones' (Current fig 6 citation in the conclusion – to be removed)
References
1. |
Sarkar R, Bansal A, Ailawadi P. Future therapies in melasma: What lies ahead? Indian J Dermatol Venereol Leprol 2020;86:8-17.
[Google Scholar]
|
Fulltext Views
2,818
PDF downloads
1,348